Table 2 Therapeutic efficacy and FiO2 requirements at varying doses of HFA-BDPa
From: Inhaled corticosteroids in ventilated preterm neonates: a non-randomized dose-ranging study
Variablea | 200 μg bid (n = 11) | 400 μg bid (n = 11) | 600 μg bid (n = 10) | 800 μg bid (n = 9) | p-value |
|---|---|---|---|---|---|
Age at commencement of therapy (days), median (range) | 21 (12, 27) | 26 (10, 28) | 22.5 (14, 26) | 22 (12, 28) | 0.76 |
Pre-treatment FiO2, mean (SD) | 0.40 (0.086) | 0.39 (0.039) | 0.40 (0.10) | 0.37 (0.044) | 0.78 |
Post-treatment FiO2, mean (SD) | 0.40 (0.074) | 0.33 (0.071) | 0.32 (0.075) | 0.30 (0.064) | 0.02 |
Therapeutic efficacy | 2/11 | 2/11 | 3/10 | 3/9 | 0.80 |